Author: et

Hua Medicine Announces that the Pharmaceutical Service of Hong Kong Department of Health of China has Officially Accepted the Application for Marketing Authorization of the New Drug Dorzagliatin

Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA). Builds on China approval and strong Phase III and real-world clinical results showing durable glucose control and safety. Positions Hong Kong as a strategic

More

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

SHENZHEN, Sept 28, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate

More